Q-omics provides the consensus-scored PIN4 profile across patient tissues and cancer cell-line models. PIN4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PIN4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PIN4 protein abundance shows 17,889 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRC, and LSCC as cancer lineages where PIN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIN4 survival associations across molecular data types. PIN4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIN4 RNA expression–survival associations across cancer types. High PIN4 expression shows unfavorable associations in KICH, LIHC, UVM, COAD and HNSC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for PIN4 RNA expression.
This table summarizes PIN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PIN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIN4 shows higher tumor expression in KIRC, HNSC, LIHC, COAD, LUAD and BLCA. The KIRC box plot shows higher PIN4 RNA expression in tumor versus normal tissue (log2 FC = +0.366, t-test p < 0.001).
This table shows molecular features associated with PIN4 in patient tissues and cancer cell lines. In patient samples, PIN4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
